MOUD Buprenorphine Sublocade denied as not FDA-approved for this use by Express Scripts?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Express Scripts typically requires
Sublocade requires 7+ days sublingual buprenorphine stabilization before LA injectable approved.
What works in the appeal
Patient-specific justification: prior buprenorphine non-adherence, diversion concerns, work/travel adherence challenges, prior overdose, pregnancy. ASAM NPG OUD 2020. Cite HOFER pivotal (Haight 2019, Lancet). MHPAEA 2024 Final Rule NQTL — demand comparative analysis.
The Express Scripts angle on MOUD Buprenorphine Sublocade
## Why Express Scripts Issues a "Not FDA-Approved" Denial for Sublocade — and How to Correct It
A "not FDA-approved" denial for Sublocade (buprenorphine extended-release subcutaneous injection) is almost always an administrative or system error. Sublocade received full FDA approval for moderate-to-severe opioid use disorder in adults following a standard new drug application review process. It is not an off-label use, a compounded product, or an investigational agent.
These denials typically arise from one of three sources: (1) an outdated drug database in ESI's utilization management system that has not been refreshed to reflect the drug's approval; (2) a coding or NDC error on the pharmacy or prescriber claim; or (3) a plan-level formulary exclusion that has been miscoded in the denial letter as "not FDA-approved" rather than the more accurate "non-formulary" or "not covered." Identifying which scenario applies determines the fastest resolution path.
## Federal Appeal Rights
- Internal appeal (ACA §2719 / ERISA §503): File within 180 days of the denial. Plans must respond within 30 days (pre-service) or 60 days (post-service).
- Expedited review: If the patient's MOUD treatment is at risk of interruption, request expedited internal review — response required within 72 hours.
- External independent review (ACA §2719): "Not FDA-approved" is a clinical determination subject to external review. External reviewers are independent of ESI and the plan. You have approximately four months from the denial to initiate external review.
- State insurance department complaint: A factually incorrect denial (denying an FDA-approved drug as unapproved) is a strong basis for a regulatory complaint, which often produces faster resolution than the internal appeal process.
## The Appeal Process
1. Verify the denial basis: Confirm whether the denial letter cites "not FDA-approved" as the specific reason or whether this is a miscoded formulary exclusion. 2. Check the NDC and claim coding: Contact the dispensing pharmacy and prescriber to confirm the correct NDC was submitted and matched to Sublocade's FDA-approved product. 3. Gather FDA approval evidence: Sublocade's FDA approval information is publicly available at FDA.gov — include a reference to it in the appeal. 4. File a written internal appeal with the documentation below, explicitly stating that the denial basis is factually incorrect. 5. File a concurrent state insurance department complaint if the denial misrepresents an FDA-approved product as unapproved. 6. Request external review if the internal appeal is not resolved in your favor.
## Documentation to Gather
- FDA approval reference: Cite Sublocade's NDA approval and FDA-approved labeling (publicly available at FDA.gov), confirming it is not investigational.
- Correct claim coding: Documentation from the pharmacy showing the NDC submitted and its match to the FDA-approved Sublocade product.
- Diagnosis and prescriber credentials: DSM-5 OUD diagnosis documentation and confirmation that the prescriber has the appropriate certification to prescribe buprenorphine.
- Prescriber medical-necessity letter: A brief letter confirming the product is FDA-approved for this indication and that prescribing is consistent with the approved label.
## Criteria-Mapping Structure
| Denial Basis Stated | Factual Rebuttal | |---|---| | Product not FDA-approved | FDA approved Sublocade for moderate-to-severe OUD in adults; cite FDA.gov | | Incorrect NDC / coding error | Pharmacy-confirmed NDC matches FDA-approved product | | Underlying formulary exclusion (if miscoded) | Proceed with formulary exception request and appeal | | Medical necessity for this patient | Prescriber letter with diagnosis and treatment rationale |
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →